Andrew Hopkinson

Andrew is the founder of NuVision with over 15 years’ experience in translational ophthalmic academic research at the University of Nottingham Ophthalmology department.

Andrew remains an honorary senior academic with the University and together with the multidisciplinary research team at the University of Nottingham, he continues developing innovative technologies to repair and regenerate the ocular surface. This research pioneered the development of Tereo® processing and Omnigen. He continues to research in this area, fuelling the future of innovative biotherapies for NuVision.